Analyst Laura Chico of Wedbush sees potential in Viridian Therapeutics (NASDAQ: VRDN), raising its price target to $43. Viridian Therapeutics is a biopharmaceutical company that develops treatments for patients with serious and rare diseases. The company is now moving from a development stage to a commercial one, which means it is starting to sell its products.
This positive outlook follows major news for Viridian Therapeutics. The U.S. Food and Drug Administration (FDA) has approved its new treatment, Lumvoa, for Thyroid Eye Disease (TED). As reported by Business Wire, TED is a rare autoimmune disease that causes inflammation and tissue changes around the eyes, which can be debilitating for patients.
The approval of Lumvoa positions Viridian Therapeutics to challenge an existing treatment in the market. As highlighted by Benzinga, the company now directly competes with Amgen (NASDAQ: AMGN)'s established therapy, Tepezza. This creates a new competitive landscape for the treatment of Thyroid Eye Disease and is a significant event for the company.
The new analyst price target of $43 was set when Viridian Therapeutics' stock price was $18.66. This new target suggests a potential increase of approximately 130% from that price. This reflects strong confidence in the company's future performance following the recent FDA approval and planned commercial launch of Lumvoa.
Following the news, the market shows positive activity for Viridian Therapeutics. The stock is trading at $18.64, a daily increase of 4.13%. With a trading volume over 5.55 million shares and a market capitalization of approximately $1.68 billion, the company is attracting significant investor attention. Market capitalization is the total value of a company's shares.
